What is Zyban?
Zyban was GlaxoSmithKline’s bupropion sustained-release tablet approved in May 1997 as an aid to stopping smoking; the brand is discontinued, so a Zyban prescription today is filled with generic bupropion SR labelled for smoking cessation. It contains the same active ingredient as Wellbutrin SR and must never be combined with it; seizures and neuropsychiatric changes are its key risks.1
Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3
Efficacy as a smoking-cessation aid was shown in 3 placebo-controlled trials in 1,940 non-depressed chronic smokers who also received individual counselling.1
In the dose-response trial, 36% of smokers on the usual dose had quit for the last 4 weeks of a 7-week course, compared with 17% on placebo.
Quit rates also rose on placebo in these counselling-supported trials, showing that the tablets add to, rather than replace, behavioural support.
It may be used together with a nicotine patch, and the most common reactions include insomnia, rhinitis, dry mouth, dizziness and anxiety.
Although not indicated for depression, it contains the same active ingredient as the Wellbutrin antidepressants and carries the same antidepressant suicidality warning.
